MedPath

Achievement of Goal Resting Heart Rate on B-blockers in Patients With Stable Angina and Hypertension

Completed
Conditions
Stable Angina
Hypertension
Registration Number
NCT01321242
Lead Sponsor
AstraZeneca
Brief Summary

This is a multicenter survey of Russian data on target heart rate achievement in patients with stable angina and arterial hypertension who are currently treated with beta-blockers for at least 2 months and with no dose change for a minimum of 4 weeks

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
400
Inclusion Criteria
  • Stable angina I-III class by the Canadian Cardiovascular Society Classification and concomitant primary hypertension
  • Subject is on beta-blockers treatment for at least 2 months prior to inclusion into survey, with no dose change for a minimum of 4 weeks
Exclusion Criteria
  • Use of phenylalkylamine and benzothiazepine calcium channel blockers
  • Hemodynamic significant mitral and aortic valve disease
  • Acute myocardial infarction and unstable angina within 3 months before enrolment

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Establish the proportion of patients with stable angina and hypertension on beta-blockers reaching the resting HR goals according to ACC/AHA/ACP-ASIM* Guidelines1 visit within 5 month

\*American College of Cardiology (ACC)/American Heart Association (AHA)/American College of Physicians (ACP-ASIM)

Secondary Outcome Measures
NameTimeMethod
Establish the mean dose of each beta-blocker in patients who achieved and not achieved resting HR goals1 visit within 5 month
Compare quality of life in patients who achieved and non achieved resting HR goals1 visit within 5 month
To estimate the correlation between achievement of resting HR goals according to ACC/AHA/ACP-ASIM Guidelines for the management of patients1 visits within 5 month

Trial Locations

Locations (1)

Research Site

🇷🇺

Ulyanovsk, Russian Federation

© Copyright 2025. All Rights Reserved by MedPath